{
    "organizations": [],
    "uuid": "65b65a227d8184e35d28d271c1031582753ae2b0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-lupins-jv-yl-biologics-says-phase/brief-lupins-jv-yl-biologics-says-phase-iii-clinical-trial-of-ylb113-met-with-successful-outcome-idUSFWN1PX010",
    "ord_in_thread": 0,
    "title": "BRIEF-Lupin's JV YL Biologics Says Phase III Clinical Trial Of YLB113 Met With Successful Outcome",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - Lupin Ltd:\n* JV YL BIOLOGICS SAYS PHASE III CLINICAL TRIAL OF INVESTIGATIONAL ETANERCEPT BIOSIMILAR (YLB113) HAS MET WITH SUCCESSFUL OUTCOME Source text: bit.ly/2GUNAnF Further company coverage:\n ",
    "published": "2018-02-07T13:50:00.000+02:00",
    "crawled": "2018-02-09T05:51:23.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "lupin",
        "ltd",
        "jv",
        "yl",
        "biologics",
        "say",
        "phase",
        "iii",
        "clinical",
        "trial",
        "investigational",
        "etanercept",
        "biosimilar",
        "ylb113",
        "met",
        "successful",
        "outcome",
        "source",
        "text",
        "company",
        "coverage"
    ]
}